John Delyani

Mimecast Outlook Nginx Mobile Friendly Render

biotechnology research immune medicines t cell receptor autoimmune diseases cancer treatment decode platform tcr bispecifics mrna vaccines therapeutic approaches immune synapse immunogenic epitopes tumor-specific therapies clinical development targeted immune suppression antigen presentation cd8+ t cells immune balance t cell activation biologics adaptive immune system cellular immune responses molecular science disease-relevant epitopes therapeutics pipeline precision medicine personalized therapies immune modulation biotech innovation immune evasion solid tumors hematological cancers regulatory t cells tolerizing vaccines epitope mapping immune homeostasis t cell specificity immune monitoring patient equity drug development cancer vaccines hla diversity immune responses clinical trials pharmaceutical collaboration tumor recognition immune therapy lipid nanoparticle delivery disease remission innovative therapeutics therapy scalability clinical-stage biotechnology immune therapies programmable immune medicines t cell repertoire oncology infectious diseases therapeutic innovation immune system programming patient-centric solutions strategic collaborations bristol myers squibb partnership advanced clinical trials immune synapse insights transformative treatments health conditions immune balance restoration targeted therapies immuno-oncology disease prevention patient populations healthcare institutions research partnerships biopharmaceutical industry health care health wellness & fitness hospital & health care